Transport’s Phase 2 Data Show Single Treatment SoloVir(TM) ETS Significantly Stops Progression Of Cold Sore Episode

At the 19th Annual Piper Jaffray Health Care Conference, Dr. Dennis I. Goldberg, President and Chief Executive Officer of Transport Pharmaceuticals, Inc., presented compelling clinical results of a Phase 2 study designed to evaluate the safety and efficacy of the company’s lead drug/device product, the SoloVir(TM) Electrokinetic Transdermal System (SoloVir(TM) ETS) for recurrent herpes labialis (cold sores). [click link for full article]

More: continued here

Filed under: Dermatology on December 2nd, 2007